Vanda Pharmaceuticals Inc’s recent filing unveils that its Director Mitchell Stephen Ray unloaded Company’s shares for reported $32130.0 on Jun 13 ’25. In the deal valued at $4.59 per share,7,000 shares were sold. As a result of this transaction, Mitchell Stephen Ray now holds 97,082 shares worth roughly $0.44 million.
Then, Mitchell Stephen Ray bought 7,000 shares, generating $32,159 in total proceeds.
Before that, Polymeropoulos Mihael Hristos bought 10,000 shares. Vanda Pharmaceuticals Inc shares valued at $43,995 were divested by the President and CEO at a price of $4.40 per share. As a result of the transaction, Polymeropoulos Mihael Hristos now holds 2,325,731 shares, worth roughly $10.44 million.
H.C. Wainwright initiated its Vanda Pharmaceuticals Inc [VNDA] rating to a Buy in a research note published on October 31, 2024; the price target was $18. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid July with a ‘”an Overweight”‘ rating. Jefferies also remained covering VNDA and has decreased its forecast on February 25, 2022 with a “Hold” recommendation from previously “Buy” rating. BofA Securities started covering the stock on May 12, 2021. It rated VNDA as “a Buy”.
Price Performance Review of VNDA
On Tuesday, Vanda Pharmaceuticals Inc [NASDAQ:VNDA] saw its stock fall -1.97% to $4.49. Over the last five days, the stock has lost -3.65%. Vanda Pharmaceuticals Inc shares have fallen nearly -6.26% since the year began. Nevertheless, the stocks have fallen -30.92% over the past one year. While a 52-week high of $6.63 was reached on 03/06/25, a 52-week low of $3.81 was recorded on 05/15/25.
Levels Of Support And Resistance For VNDA Stock
The 24-hour chart illustrates a support level at 4.45, which if violated will result in even more drops to 4.40. On the upside, there is a resistance level at 4.57. A further resistance level may holdings at 4.64.
